Ann: Investor Presentation, page-28

It probably could, and that's as an indirect consequence of the lack of clinical trials on most cannabinoids - there's a sizeable amount of scientific literature on the substances but only few clinical trials with BOT being apparently the first (and currently only) undertaking trials for dermatological applications.
And apparently not only the eyebrows of an oncologist could rise, those of an urologist too:
the latest internationally recognized super-doctor to commit to the medical applications of cannabinoids is none less than the guy who was the lead principal investigator for Viagra and Cialis through the FDA's approved trials: Dr Padma-Nathan.

https://www.linkedin.com/in/harin-padma-nathan-md-frcs-facs-96b0921/

There's somebody who certainly knows how to recognize a blockbuster drug (ask Pfizer about it).